AAAAAA

   
Results: 1-9 |
Results: 9
ADVANCED DIFFUSE LARGE-CELL LYMPHOMA TREATED WITH 12-WEEK COMBINATIONCHEMOTHERAPY - NATURAL-HISTORY OF RELAPSE AFTER INITIAL COMPLETE RESPONSE AND PROGNOSTIC VARIABLES DEFINING OUTCOME AFTER RELAPSE
Authors: HOSKINS PJ LE N GASCOYNE RD KLASA R SHENKIER T OREILLY S CONNORS JM
Citation: Pj. Hoskins et al., ADVANCED DIFFUSE LARGE-CELL LYMPHOMA TREATED WITH 12-WEEK COMBINATIONCHEMOTHERAPY - NATURAL-HISTORY OF RELAPSE AFTER INITIAL COMPLETE RESPONSE AND PROGNOSTIC VARIABLES DEFINING OUTCOME AFTER RELAPSE, Annals of oncology, 8(11), 1997, pp. 1125-1132
CISPLATIN ETOPOSIDE CHEMOTHERAPY FOR RECURRENT OR PRIMARILY ADVANCED CERVICAL-CARCINOMA/
Authors: ALSALEH E HOSKINS PJ PIKE JA SWENERTON KD
Citation: E. Alsaleh et al., CISPLATIN ETOPOSIDE CHEMOTHERAPY FOR RECURRENT OR PRIMARILY ADVANCED CERVICAL-CARCINOMA/, Gynecologic oncology, 64(3), 1997, pp. 468-472
TAXOL IS ACTIVE IN PLATINUM-RESISTANT ENDOMETRIAL ADENOCARCINOMA
Authors: WOO HL SWENERTON KD HOSKINS PJ
Citation: Hl. Woo et al., TAXOL IS ACTIVE IN PLATINUM-RESISTANT ENDOMETRIAL ADENOCARCINOMA, American journal of clinical oncology, 19(3), 1996, pp. 290-291
MECCA - A DEVELOPMENTAL, DOSE-INTENSIVE, NON-CROSS-RESISTANT PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER
Authors: HOSKINS PJ SWENERTON KD PIKE JA MCMURTRIE EM LEE N
Citation: Pj. Hoskins et al., MECCA - A DEVELOPMENTAL, DOSE-INTENSIVE, NON-CROSS-RESISTANT PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER, Gynecologic oncology, 63(3), 1996, pp. 345-351
PLATINUM PLUS CYCLOPHOSPHAMIDE PLUS RADIOTHERAPY IS SUPERIOR TO PLATINUM ALONE IN HIGH-RISK EPITHELIAL OVARIAN-CANCER (RESIDUAL NEGATIVE AND EITHER STAGE-I OR STAGE-II, GRADE-3, OR STAGE-III, ANY GRADE)
Authors: HOSKINS PJ SWENERTON KD WONG F MANJI MF MCMURTRIE EM LE N PIKE J
Citation: Pj. Hoskins et al., PLATINUM PLUS CYCLOPHOSPHAMIDE PLUS RADIOTHERAPY IS SUPERIOR TO PLATINUM ALONE IN HIGH-RISK EPITHELIAL OVARIAN-CANCER (RESIDUAL NEGATIVE AND EITHER STAGE-I OR STAGE-II, GRADE-3, OR STAGE-III, ANY GRADE), International journal of gynecological cancer, 5(2), 1995, pp. 134-142
TREATMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER - PAST, PRESENT AND FUTURE
Authors: HOSKINS PJ
Citation: Pj. Hoskins, TREATMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER - PAST, PRESENT AND FUTURE, Critical reviews in oncology/hematology, 20(1-2), 1995, pp. 41-59
SMALL-CELL CARCINOMA OF THE CERVIX TREATED WITH CONCURRENT RADIOTHERAPY, CISPLATIN, AND ETOPOSIDE
Authors: HOSKINS PJ WONG F SWENERTON KD PIKE JA MANJI M MCMURTRIE E ACKER B LERICHE J
Citation: Pj. Hoskins et al., SMALL-CELL CARCINOMA OF THE CERVIX TREATED WITH CONCURRENT RADIOTHERAPY, CISPLATIN, AND ETOPOSIDE, Gynecologic oncology, 56(2), 1995, pp. 218-225
MODERATE-RISK OVARIAN-CANCER (STAGE-I, GRADE-2 - STAGE-II, GRADE-1 ORGRADE-2) TREATED WITH CISPLATIN CHEMOTHERAPY (SINGLE-AGENT OR COMBINATION) AND PELVI-ABDOMINAL IRRADIATION
Authors: HOSKINS PJ SWENERTON KD MANJI M WONG F OREILLY SE MCMURTRIE EJ LE N ACKER B LERICHE J
Citation: Pj. Hoskins et al., MODERATE-RISK OVARIAN-CANCER (STAGE-I, GRADE-2 - STAGE-II, GRADE-1 ORGRADE-2) TREATED WITH CISPLATIN CHEMOTHERAPY (SINGLE-AGENT OR COMBINATION) AND PELVI-ABDOMINAL IRRADIATION, International journal of gynecological cancer, 4(4), 1994, pp. 272-278
ORAL ETOPOSIDE IS ACTIVE AGAINST PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER
Authors: HOSKINS PJ SWENERTON KD
Citation: Pj. Hoskins et Kd. Swenerton, ORAL ETOPOSIDE IS ACTIVE AGAINST PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER, Journal of clinical oncology, 12(1), 1994, pp. 60-63
Risultati: 1-9 |